Android app on Google Play

Bristol-Myers Squibb (BMY) Acquires Amylin (AMLN) for $31/Share

June 30, 2012 9:57 AM EDT Send to a Friend
Get Alerts AMLN Hot Sheet
Trade AMLN Now!
Join SI Premium – FREE
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) agreed to be acquired by Bristol-Myers Squibb Company (NYSE: BMY) for $31.00 per share in cash, or approximately $5.3 billion.

Including Amylin's net debt and a contractual payment obligation to Eli Lilly & Company (NYSE: LLY), together totaling about $1.7 billion, is approximately $7 billion.

In March, Amylin rejected a $22 offer from Bristol-Myers and started an auction process. Today's deal comes at a 41 percent premium to the prior offer.

With the deal, Bristol-Myers Squibb is gaining approved and marketed products for Type 2 Diabetes, including BYETTA and BYDUREON.

For Bristol-Myers Squibb, the transactions are expected to be dilutive to Non-GAAP earnings per share (EPS) in 2012 and 2013 by approximately $0.03, becoming slightly accretive starting in 2014 with meaningful accretion expected in the later part of the decade.

Under the terms of the definitive merger agreement, Bristol-Myers Squibb will commence a cash tender offer to purchase all of the outstanding shares of Amylin’s common stock for $31.00 per share. The closing of the tender offer is subject to customary terms and conditions, including the tender of a number of shares that constitutes at least a majority of Amylin’s outstanding shares of common stock, on a fully diluted basis, and expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

The companies expect the tender offer to close approximately thirty days after commencement of the tender offer.




You May Also Be Interested In


Related Categories

Hot List, Hot M&A, Mergers and Acquisitions

Related Entities

Earnings

Add Your Comment